Penumbra (PEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra's AI-guided aspiration system and scalable platform uniquely position it as a leader in stroke and PE intervention, justifying a Buy rating. First-mover advantage in intelligent thrombectomy, expanding European reimbursement, and an aging population create strong long-term growth tailwinds. Despite premium valuation multiples, PEN's innovation, ecosystem, and divestiture of non-core assets support its growth and margin expansion potential.
Zacks names PEN, ITGR and ANGO as medical device stocks riding genAI advances, despite global and inflationary headwinds.
Penumbra launches FDA-cleared Ruby XL System to bring advanced coil technology to high-flow embolization procedures.
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?
PEN has shown notable strength over the past year, driven by the performance of its core U.S. thrombectomy business. Solid international prospects instill optimism.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.